Previous 10 | Next 10 |
PASADENA, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s lead compound, LB-100, to enter the brain ...
Studies to use genome wide functional genetic techniques to identify effective drug combinations and new drug targets for its lead clinical compound, LB-100 PASADENA, CA, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: L...
PASADENA, CA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings , Inc. ( Nasdaq: LIXT ) announced entry into a collaboration with the Netherlands Cancer Institute , Amsterdam (NKI) , one of the world’s leading comprehensive cancer centers, and O...
A series of recent pre - clinical reports demonstrat e s LB-100’s effectiveness in various non - neoplastic diseases that may benefit from PP2A inhibition PASADENA, C...
Score Media and Gaming (NASDAQ:SCR) +65% Penn National Gaming inks deal to acquire Score Media and Gaming Ensysce Biosciences (NASDAQ:ENSC) +38% announces notice of allowance from the U.S. Patent and trademark office for Patent entitled “compositions comprising enzyme-cl...
3 Hot Biotech Penny Stocks to Know About in August Biotech penny stocks have remained some of the most popular penny stocks to watch throughout the past year and a half. The obvious reason behind this is the impact of the pandemic and the resulting attention on the biotech industry....
Gainers: Arcturus Therapeutics ARCT +35%, Translate Bio TBIO +29%, Flora Growth (NASDAQ:FLGC) +27%, Lixte Biotechnology (NASDAQ:LIXT) +27%, Outlook Therapeutics (NASDAQ:OTLK) +23%. Losers: Neuronetics STIM -39%, Bright Health BHG -19%,...
A Pre-Clinical Study Reports that LB -100 Potentiates Standard Therapy f or Small Cell Lung Cancer Providing a Strong Rational e f or a Clinical Trial o f LB -100 i n Small Cell Lung Cancer Recently Initiated a t ...
Altadena, CA, July 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . ( Nasdaq:LIXTE ) a clinical-stage drug discovery company developing pharmacologically active drugs for improving cancer treatments, commented on pre-clinical research demonstrating that inhibitio...
Altadena, CA, July 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . ( Nasdaq: LIXT ) (“Lixte” or the “Company”) noted that Julio Pimentel, a fourth-year doctoral student in the Wayne State University School of Medicine’s Cancer ...
News, Short Squeeze, Breakout and More Instantly...
Lixte Biotechnology Holdings Inc. Company Name:
LIXT Stock Symbol:
OTCMKTS Market:
Lixte Biotechnology Holdings Inc. Website:
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ...
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ȁ...
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( ...